We discovered a trend toward a stronger antiproliferative effect on primary AML cells with the SYK inhibitors in patients with FLT3; however, only for the highest concentrations of fostamatinib (1.0 μM) and TAK-659 (0.5 μM) did the difference in antiproliferative effects reach statistical significance (Figure 3). The gene discussed is FLT3; the disease is acute myeloid leukemia.